EF
SUPN icon

Empowered Funds’s Supernus Pharmaceuticals SUPN Stock Holding History

Empowered Funds’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-47,093
Closed -$1.68M – 696
2022
Q4 		$1.68M Buy
+47,093
New +$1.64M 0.11% 198

Other funds holding SUPN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Empowered Funds's SUPN Position: Q1 2026 in Review

Empowered Funds opened a new position in Supernus Pharmaceuticals (SUPN) in Q1 2026: 5,107 shares worth $264K. The stake represents ﹤0.01% of the portfolio and ranks #1883 among its holdings. This is a return to the name: Empowered Funds previously reported a position in SUPN as recently as Q1 2025.

Empowered Funds first reported a position in SUPN in Q1 2023 and has held it in 6 quarters since. The position peaked at $4.51M in Q1 2023. 327 funds tracked by Wall St. Rank hold SUPN as of Q1 2026.

  • Empowered Funds held 5,107 shares of Supernus Pharmaceuticals worth $264K as of Q1 2026.
  • Supernus Pharmaceuticals was a new Empowered Funds position in Q1 2026.
  • Supernus Pharmaceuticals made up ﹤0.01% of Empowered Funds's portfolio in Q1 2026, its #1883 holding.
  • Empowered Funds first reported a position in Supernus Pharmaceuticals in Q1 2023 and has held it in 6 quarters since.
  • Empowered Funds's Supernus Pharmaceuticals position peaked at $4.51M in Q1 2023.
  • 327 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q1 2026.

Based on Empowered Funds's 13F filing for Q1 2026, filed 15 May 2026.